falsefalse

Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse - Episode 8

CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024

, , , ,

Panelists discuss how the KARMMA-3 study’s design, patient population, and efficacy outcomes—including overall survival data—inform the approval of ide-cel, as well as the implications of CARTITUDE-4’s recent findings on treatment selection and approaches for cilta-cel in chimeric antigen receptor T-cell therapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates
    EP. 2: Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma
    EP. 3: Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies
    EP. 4: MRD Negativity as a Trial Outcome and Its Use in Clinical Practice
    EP. 5: Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma
    EP. 6: Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
    EP. 7: Considerations for Use of CAR T-cell Therapy in Multiple Myeloma
    Now Viewing
    EP. 8: CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024
    EP. 9: Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers
    EP. 10: Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life
    1. Dr Ajai Chari to Dr Martin: Let’s dive deeper into the KARMMA-3 study that got ide-cel approved. Dr Martin: Can you please review the KARMMA-3 study design, patient population, and efficacy outcomes including overall survival (OS) data?

    Resource Link:

    1. Dr Ajai Chari to Dr Callander: Now that we have discussed KARMMA-3, let’s review CARTITUDE-4. Dr Callander: Can you please review the CARTITUDE-4 study design, patient population, and recently presented IMS 2024 CARTITUDE-4 OS data updates

    Resource Link

    Related Content:

    Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse
    Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers
    Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life
    Considerations for Use of CAR T-cell Therapy in Multiple Myeloma
    x